Double attack: vaccine boosts CAR T-Cells against tough lymphoma
NCT ID NCT05801913
First seen Mar 08, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This early-phase study tests whether combining a patient's own modified immune cells (CAR T-cells) with a special vaccine is safe and possible for people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The CAR T-cells are designed to find and kill cancer cells, while the vaccine may help the CAR T-cells work better and last longer. About 15 participants will receive this combination therapy to see if it can be done safely and if it helps control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.